Products for Research Use Only
RegisterLogin

Vazegepant

CAT: 0804-HY-134992-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-134992-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide CGRP receptor antagonist with potential for acute research in migraine, can be administered intranasally. CGRP is an important trigger in migraine pathophysiology[1][2][3][4].
CAS Number
1337918-83-8
Product Name Alternative
Zavegepant; BHV-3500
UNSPSC
12352005
Target
CGRP Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/vazegepant.html
Concentration
10mM
Purity
99.54
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(N1CCC(C2=CC3=C(NC2=O)C=CC=C3)CC1)N[C@H](CC4=CC5=C(NN=C5)C(C)=C4)C(N6CCN(C7CCN(C)CC7)CC6)=O
Molecular Formula
C36H46N8O3
Molecular Weight
638.80
References & Citations
[1]Moreno-Ajona D, et al. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020 Jun;33 (3) :309-315.|[2]Gene M Dubowchik, et al. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.|[3]Capi M, De Angelis V, De Bernardini D, et al. Zavegepant[M]//Novel Synthetic Drugs in Migraine. Cham: Springer International Publishing, 2022: 67-72.|[4]Jéssica Barreto Ribeiro Dos Santos, et al. Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. Eur J Pharmacol.2022 May 5:922:174902.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
T38734-01Vazegepant
BUP02968-01Vazegepant hydrochloride
JH918843Vazegepant HCl

Popular Products